Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer

FLEX Study data shows that patients with MammaPrint High Read More

2026-06-24T17:12:21-04:00June 25th, 2026|Press Releases|

Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer

Additional research highlights integration of BluePrint molecular subtyping and Read More

2026-05-19T16:41:07-04:00May 21st, 2026|ASCO, Press Releases|

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More

2026-03-11T15:42:05-04:00January 20th, 2026|Press Releases|
Go to Top